Immune System Diseases

905 trials 381 recruiting

Filter these 905 trials by phase, country and sponsor.

Open in Search →

Evaluation of Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Patients with Moderate to Severe Atopic Derma… Ended

2022-502937-24-00 Atopic Dermatitis 5 2019-01-02
A Study of Efficacy, Safety, and Pharmacokinetics of Guselkumab in the Treatment of Chronic Plaque Psoriasis in Pediatric Participants Ended

2023-503378-19-00 Chronic Plaque Psoriasis 5 2018-08-23
A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease Ended

2023-504736-18-00 Moderately to Severely Active Crohn's Disease 10 2018-07-26
RAM-MS Ended

2024-510630-40-00 Multiple sclerosis 5 2018-02-12
A Phase Ib-II Study of tazemetostat (EPZ-6438) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or high risk Follicular Lymphoma (FL… Ended

2024-515846-18-00 Newly diagnosed Diffuse Large B Cell Lymphoma 7 2016-09-19
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Rheumatoid Arthritis who are on a Stable Dose of Meth… Ended

2022-501017-31-00 Rheumatoid arthritis 5 2016-05-10
Study of CC-97540 (BMS-986353), CD19-CAR T Cells, in Participants with Active SLE Despite Immunosuppressants (Breakfree-SLE) Halted

2024-519278-37-00 Lupus Nephritis 4 2025-10-22
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of T7-010 in Healthy Participants. Halted

2024-518440-20-00 Autoimmune Diseases (Healthy Volunteers) 1 2025-09-16
Methotrexate PK (in combination with Novobiocin) in RA patients Halted

2025-522531-34-00 Rheumatoid arthritis 3 2025-08-19
A phase 1, randomized, double-blind, single-center, placebo-controlled first-in-human trial to assess the safety, tolerability, pharmacokine… Halted

2023-510371-55-00 Complement-mediated diseases 1 2024-11-14
A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with RMS, PMS, or MG(Breakfree-2) Halted

2023-507820-22-00 Myasthenia gravis (MG) 3 2024-05-22
A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with Severe, Refractory Autoimmune Diseases (Breakfree-1) Halted

2023-503823-24-01 Systemic Sclerosis 3 2024-04-15
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Deucrava… Ended

2025-523838-13-00 plaque psoriasis 2 2026-03-24
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Deucrava… Ended

2025-523839-18-00 plaque psoriasis 2 2026-03-24
A study to compare how the body absorbs different formulations of a new medicine, and how food affects drug absorption, in healthy participa… Ended

2025-523430-14-00 Psoriasis 3 2025-12-24
Determination of Blomia tropicalis allergen extract in prick test units Ended

2024-515169-33-00 Allergy to Blomia tropicalis 4 2025-11-25
A clinical study of MK-6050 in healthy people (MK-6050-001) Ended

2025-523861-58-00 Hidradenitis suppurativa 1 2025-11-24
Comparison of Prefilled syringe and Autoinjector presentations of FYB202 Ended

2025-522422-13-00 Chronic inflammatory diseases 2 2025-11-15
Assessment of the safety and effects on the body of investigational products when used on psoriatic skin Ended

2025-522446-51-00 Plaque psoriasis 3 2025-10-17
Immunosuppressive drug bioequivalence in kidney transplant recipients – Prograf and CellCept Ended

2025-521800-22-00 Organ transplantation 6 2025-08-04
The CALiPSO-1 Study: A Study of CNTY-101, a CD19-targeted CAR iNK Cell Product, in Participants with Refractory B cell-mediated Autoimmune D… Ended

2024-518797-13-00 systemic lupus erythematosus [SLE]/lupus nephritis [LN] 3 2025-07-10
(IPCOM) Influence of Proton pump inhibitor CO-medication on the absorption of innovator and generic formulations of Mycophenolate mofetil Ended

2024-517043-32-00 Post Transplantation Patients 6 2025-07-08
A study to learn how the study medicine called [14C]PF-07054894 is processed by the body. Ended

2024-519882-23-00 Inflammatory bowel disease. 3 2025-06-13
Phase 1 study on SAR443122 bioavailability and food effect in healthy adults Ended

2025-521073-13-00 Colitis ulcerative 2 2025-06-11